文献速递中医内科中药与中成药合理使用

含水蛭中药治疗冠心病的临床疗效:系统评价与Meta分析

The clinical efficacy of herbal medicines containing leeches in the treatment of coronary heart disease: a systematic review and meta-analysis.
PubMed 文献 · Front Pharmacol · 2025-10-17

该系统评价与Meta分析检索截至2025年2月的随机对照试验,评估含水蛭中药治疗冠心病的效果与安全性。

要点

  • 含水蛭中药可显著提高冠心病患者总有效率和心电图疗效。
  • 含水蛭中药改善血液流变学指标,且不良事件未增加。
  • 亚组分析提示含水蛭中药在提高总有效率、心电图和血液流变学方面尤其有效。

核心结论

  • 含水蛭中药治疗冠心病具有显著临床获益,尤其改善心电图结局和血液指标。
  • 含水蛭中药有效且安全,不良事件率未较常规治疗增加。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、EMBASE、Web of Science、Cochrane Library、CNKI、万方、维普至2025年2月。

主要发现

  • 总有效率:OR=3.70,95%CI(3.19,4.31),Z=17.05,P<0.00001。
  • 心电图疗效:OR=2.58,95%CI(2.23,2.99),P<0.0001。
  • 血液流变学参数显著改善。
  • 亚组分析提示含水蛭治疗对提高总有效率、心电图结局和血液流变学指标尤其有效。
  • 不良事件率未较常规治疗增加。

关键数值与推荐

  • 总有效率采用OR及95%CI分析,心电图疗效采用OR及95%CI分析。
  • 血液流变学参数采用标准化均数差(SMD)及95%CI评估。
  • 安全性采用比值比(OR)及95%CI评估。

临床怎么用

  • 含水蛭中药可作为冠心病辅助治疗,尤其适用于需改善心电图和血液流变学的患者。
  • 临床应用时需关注患者个体特征,亚组分析提示特定人群可能获益更明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronary heart disease (CHD) is a leading global cause of mortality, contributing to angina, arrhythmia, myocardial infarction, heart failure, and sudden death. Traditional treatments, including antiplatelet drugs, statins, β-blockers, and coronary stents, have notable side effects such as gastrointestinal bleeding and liver or muscle dysfunction, with post-operative stent complications. Recent studies have identified bioactive substances in leeches, particularly the natural anticoagulant hirudin, which inhibits thrombin and may help mitigate complications of coronary artery disease. Hirudin inhibits thrombin, reduces platelet aggregation, and lowers thrombosis risk. This meta-analysis evaluates the clinical efficacy and safety of Chinese herbal medicines containing leech in treating CHD, focusing on cardiovascular outcomes and adverse events. METHODS: A systematic search of databases including PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), WanFang Data (Wanfang), and VIP China Science and Technology Journal Database (VIP) was conducted to identify randomized controlled trials (RCTs) involving leech-containing Chinese herbal medicines for CHD patients up until February 2025. Key efficacy outcomes analyzed were total effective rate, ECG efficacy, and hemorheological parameters, while adverse event rates assessed treatment safety. The meta-analysis used Standardized Mean Difference (SMD) and 95% confidence intervals (CI) to assess efficacy, and Odds Ratio (OR) with 95% CI for safety. Subgroup analyses examined the relationship between therapeutic effects and patient characteristics. RESULTS: Sixty-five studies involving 7,221 patients were included. The results showed that leech-based treatments significantly improved the total effective rate [OR = 3.70, 95% CI (3.19, 4.31), Z = 17.05, P < 0.00001] and ECG efficacy [OR = 2.58, 95% CI (2.23, 2.99), P < 0.0001], along with significant improvements in hemorheological parameters. Subgroup analysis indicated leech treatments were particularly effective for improving the total effective rate, ECG outcomes, and hemorheological indices. Importantly, adverse event rates did not increase compared to conventional treatments. CONCLUSION: Chinese herbal medicines containing leeches provide significant clinical benefits for CHD, particularly in improving ECG outcomes and blood parameters. These findings suggest that leech-based treatments are both effective and safe, with no increase in adverse events. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, Identifier CRD42024564675.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ziyuan Z, Di Y, Mei L, et al. The clinical efficacy of herbal medicines containing leeches in the treatment of coronary heart disease: a systematic review and meta-analysis. Front Pharmacol. 2025. PMID: 41181591. doi:10.3389/fphar.2025.1643611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。